185 related articles for article (PubMed ID: 23601006)
1. Inhibitors in haemophilia B: the Italian experience.
Castaman G; Bonetti E; Messina M; Morfini M; Rocino A; Scaraggi FA; Tagariello G;
Haemophilia; 2013 Sep; 19(5):686-90. PubMed ID: 23601006
[TBL] [Abstract][Full Text] [Related]
2. Successful second ITI with factor IX and combined immunosuppressive therapy. A patient with severe haemophilia B and recurrence of a factor IX inhibitor.
Holstein K; Schneppenheim R; Schrum J; Bokemeyer C; Langer F
Hamostaseologie; 2014; 34 Suppl 1():S5-8. PubMed ID: 25382771
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006).
Chitlur M; Warrier I; Rajpurkar M; Lusher JM
Haemophilia; 2009 Sep; 15(5):1027-31. PubMed ID: 19515028
[TBL] [Abstract][Full Text] [Related]
4. Development of anaphylactic shock in haemophilia B patients with inhibitors.
Warrier I; Lusher JM
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S125-8. PubMed ID: 9819043
[TBL] [Abstract][Full Text] [Related]
5. Incidence of factor IX inhibitor development in severe haemophilia B patients treated with only one brand of high purity plasma derived factor IX concentrate.
Parquet A; Laurian Y; Rothschild C; Navarro R; Guérois C; Gay V; Durin A; Peynet J; Sultan Y
Thromb Haemost; 1999 Oct; 82(4):1247-9. PubMed ID: 10544907
[TBL] [Abstract][Full Text] [Related]
6. Inhibitor development in haemophilia B: an orphan disease in need of attention.
DiMichele D
Br J Haematol; 2007 Aug; 138(3):305-15. PubMed ID: 17614818
[TBL] [Abstract][Full Text] [Related]
7. Rituximab and desensitization for a patient with severe factor IX deficiency, inhibitors, and history of anaphylaxis.
Alexander S; Hopewell S; Hunter S; Chouksey A
J Pediatr Hematol Oncol; 2008 Jan; 30(1):93-5. PubMed ID: 18176193
[TBL] [Abstract][Full Text] [Related]
8. Factor IX antibody and immune tolerance.
Warrier I
Vox Sang; 1999; 77 Suppl 1():70-1. PubMed ID: 10529693
[TBL] [Abstract][Full Text] [Related]
9. F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity.
Miller CH; Benson J; Ellingsen D; Driggers J; Payne A; Kelly FM; Soucie JM; Craig Hooper W;
Haemophilia; 2012 May; 18(3):375-82. PubMed ID: 22103590
[TBL] [Abstract][Full Text] [Related]
10. Factor IX inhibitors in haemophilia B: A report of National Haemophilia Registry in China.
Dou X; Zhang W; Poon MC; Zhang X; Wu R; Feng X; Yang L; Cheng P; Chen S; Wang Y; Zhou H; Huang M; Song Y; Jin C; Zhang D; Chen L; Liu W; Zhang L; Xue F; Yang R
Haemophilia; 2023 Jan; 29(1):123-134. PubMed ID: 36163649
[TBL] [Abstract][Full Text] [Related]
11. Immune tolerance in haemophilia: the long journey to the fork in the road.
DiMichele DM
Br J Haematol; 2012 Oct; 159(2):123-34. PubMed ID: 22924753
[TBL] [Abstract][Full Text] [Related]
12. Risk factors associated with inhibitor development in Chinese patients with haemophilia B.
Zhou J; Ding Q; Chen Z; Yang H; Lin L; Wang H; Wang X; Wu R
Haemophilia; 2015 Jul; 21(4):e286-93. PubMed ID: 25929987
[TBL] [Abstract][Full Text] [Related]
13. A retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia B.
Recht M; Pollmann H; Tagliaferri A; Musso R; Janco R; Neuman WR
Haemophilia; 2011 May; 17(3):494-9. PubMed ID: 21518148
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of a recombinant factor IX (Bax326) in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open-label, uncontrolled, multicentre, phase III study.
Windyga J; Lissitchkov T; Stasyshyn O; Mamonov V; Ghandehari H; Chapman M; Fritsch S; Wong WY; Pavlova BG; Abbuehl BE
Haemophilia; 2014 Sep; 20(5):651-8. PubMed ID: 24697870
[TBL] [Abstract][Full Text] [Related]
15. Immune tolerance induction with mycophenolate-mofetil in two children with haemophilia B and inhibitor.
Klarmann D; Martinez Saguer I; Funk MB; Knoefler R; von Hentig N; Heller C; Kreuz W
Haemophilia; 2008 Jan; 14(1):44-9. PubMed ID: 18081836
[TBL] [Abstract][Full Text] [Related]
16. Survey of the anti-factor IX immunoglobulin profiles in patients with hemophilia B using a fluorescence-based immunoassay.
Boylan B; Rice AS; Neff AT; Manco-Johnson MJ; Kempton CL; Miller CH;
J Thromb Haemost; 2016 Oct; 14(10):1931-1940. PubMed ID: 27501440
[TBL] [Abstract][Full Text] [Related]
17. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk.
Thorland EC; Drost JB; Lusher JM; Warrier I; Shapiro A; Koerper MA; Dimichele D; Westman J; Key NS; Sommer SS
Haemophilia; 1999 Mar; 5(2):101-5. PubMed ID: 10215957
[TBL] [Abstract][Full Text] [Related]
18. Induction of immune tolerance and suppression of anaphylaxis in a child with haemophilia B by simple plasmapheresis and antigen exposure.
Barnes C; Rudzki Z; Ekert H
Haemophilia; 2000 Nov; 6(6):693-5. PubMed ID: 11122398
[TBL] [Abstract][Full Text] [Related]
19. Desensitization and immune tolerance induction in children with severe factor IX deficiency; inhibitors and adverse reactions to replacement therapy: a case-report and literature review.
Bon A; Morfini M; Dini A; Mori F; Barni S; Gianluca S; de Martino M; Novembre E
Ital J Pediatr; 2015 Feb; 41():12. PubMed ID: 25887512
[TBL] [Abstract][Full Text] [Related]
20. Low prevalence of inhibitor antibodies in the Canadian haemophilia population.
Webert KE; Rivard GE; Teitel J; Carcao M; Lillicrap D; St-Louis J; Walker IR
Haemophilia; 2012 May; 18(3):e254-9. PubMed ID: 22077390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
